Broad Anti-Eczema Effects Seen With IL-22 Inhibitor

by | Dec 12, 2025 | Health

Spread the love
In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments